<DOC>
	<DOCNO>NCT03042052</DOCNO>
	<brief_summary>Aims study assess long-term outcome detrusor injection OnabotulinumtoxinA ( Botox® injection ) associate clean intermittent-catheterization ( CIC ) treatment neurogenic detrusor overactivity ( NDO ) identify risk factor failure .</brief_summary>
	<brief_title>Toxin Retrospective Study</brief_title>
	<detailed_description>Neurogenic detrusor overactivity ( NDO ) remain major concern patient neurological disease . Fifty eighty percent patient multiple sclerosis ( MS ) traumatic spinal cord injury ( SCI ) 60 % patient myelomeningocele suffer urinary incontinence episode ( UI ) due NDO . NDO characterize involuntary detrusor contraction fill phase , leading leakage increase bladder pressure , , precipitate renal failure . Detrusor injection OnabotulinumtoxinA ( Botox® ) , license worldwide recommended second line therapy treatment urinary incontinence due NDO failure anticholinergic drug ( Grade A ) . These recommendation base result international multicentric , randomize controlled trial . These study establish clinical benefit , significant decrease urinary incontinence episode , also urodynamic benefit . There data real prevalence failure Botox® long term . Thus , aim study assess long-term outcome detrusor injection Botox® associate clean intermittent-catheterization ( CIC ) treatment NDO identify risk factor failure .</detailed_description>
	<mesh_term>Urinary Bladder , Neurogenic</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>NDO due MS , SCI spinabifida . followup ≥3 year first Botox® injection . Performing clean intermittent catheterization bladder surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>